Telaprevir and Ribavirin Interaction: Higher Ribavirin Levels Are Not Only Due to Renal Dysfunction during Triple Therapy

被引:3
作者
Gutierrez-Valencia, Alicia [1 ,2 ]
Ruiz-Valderas, Rosa [1 ,2 ]
Ben-Marzouk-Hidalgo, Omar J. [1 ,2 ]
Torres-Cornejo, Almudena [1 ,2 ]
Espinosa, Nuria [1 ]
Castillo-Ferrando, Juan R. [3 ]
Viciana, Pompeyo [1 ,2 ]
Lopez-Cortes, Luis F. [1 ,2 ]
机构
[1] Hosp Univ Virgen del Rocio, Enfermedades Infecciosas Microbiol & Med Prevent, Seville, Spain
[2] Univ Seville, CSIC, Hosp Univ Virgen del Rocio, Inst Biomed Sevilla IBiS, Seville, Spain
[3] Hosp Univ Virgen del Rocio, Farmacol Clin, Seville, Spain
关键词
CHRONIC HEPATITIS-C; SUSTAINED VIROLOGICAL RESPONSE; PEGYLATED INTERFERON; INFECTED PATIENTS; COINFECTED PATIENTS; VIRUS-INFECTION; PEGINTERFERON-ALPHA; TUBULAR SECRETION; DRUG-INTERACTIONS; PLUS RIBAVIRIN;
D O I
10.1128/AAC.04795-14
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
A higher incidence of anemia has been observed during the treatment of hepatitis C virus genotype 1 (HCV-1) infection with pegylated alpha interferon (pegIFN-alpha), ribavirin, and telaprevir. We assessed the impacts that concomitant administration of telaprevir and changes in the glomerular filtration rate have on ribavirin plasma levels. The minimum concentrations of ribavirin in plasma (ribavirin C-min) determined during triple therapy including telaprevir were compared with those observed after telaprevir withdrawal and those observed in the same subjects and in a large cohort during a previous course of pegIFN-alpha plus ribavirin. Intensive pharmacokinetic sampling for ribavirin was performed at steady state during the triple-therapy phase. Ribavirin levels were measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Twenty-seven HCV-1/HIV-coinfected patients were enrolled. The median ribavirin C-min for triple therapy (4.08 mu g/ml; range, 2.14 to 5.56 mu g/ml) was higher than that observed after telaprevir withdrawal (1.96 mu g/ml; range, 0.41 to 3.45 mu g/ml) (P < 0.001) and that observed for 125 HCV-1/HIV-coinfected patients treated only with pegIFN-alpha plus ribavirin (1.65 mu g/ml; range, 0.41 to 5.56 mu g/ml) (P < 0.001). The estimated glomerular filtration rate (eGFR) decreased > 20% from the baseline value in 11 of 27 patients and became normal after telaprevir removal in almost all cases. There was a negative correlation between eGFR and ribavirin clearance (r(2) = 0.257; P = 0.064) but not the ribavirin area under the concentration-time curve from 0 to 12 h (AUC(0-12)) (r(2) = 0.001; P = 0.455). Thus, there is a significant pharmacokinetic interaction between telaprevir and ribavirin that results in very high ribavirin levels, which explains the excess of toxicity observed with this drug combination. A blockade of the proximal tubular transporters might be implicated in both the increase in plasma creatinine and the high ribavirin levels.
引用
收藏
页码:3257 / 3262
页数:6
相关论文
共 38 条
[1]   Interleukin-28B Genetic Variants and Hepatitis Virus Infection by Different Viral Genotypes [J].
Antonio Montes-Cano, Marco ;
Raul Garcia-Lozano, Jose ;
Abad-Molina, Cristina ;
Romero-Gomez, Manuel ;
Barroso, Natalia ;
Aguilar-Reina, Jose ;
Nunez-Roldan, Antonio ;
Francisca Gonzalez-Escribano, Maria .
HEPATOLOGY, 2010, 52 (01) :33-37
[2]   Clinical trial:: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alfa-2a plus ribavirin [J].
Bain, V. G. ;
Lee, S. S. ;
Peltekian, K. ;
Yoshida, E. M. ;
Deschenes, M. ;
Sherman, M. ;
Bailey, R. ;
Witt-Sullivan, H. ;
Balshaw, R. ;
Krajden, M. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 28 (01) :43-50
[3]   Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir [J].
Boglione, L. ;
De Nicolo, A. ;
Cusato, J. ;
Cariti, G. ;
Di Perri, G. ;
D'Avolio, A. .
JOURNAL OF VIRAL HEPATITIS, 2014, 21 (04) :260-263
[4]   Impact of ribavirin plasma level on sustained virological response in patients treated with pegylated interferon and ribavirin for chronic hepatitis C [J].
Breilh, D. ;
Foucher, J. ;
Castera, L. ;
Trimoulet, P. ;
Djabarouti, S. ;
Merrouche, W. ;
Couzigou, P. ;
Saux, M. -C. ;
De Ledinghen, V. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 30 (05) :487-494
[5]   Expression of Organic Anion Transporter 2 in the Human Kidney and Its Potential Role in the Tubular Secretion of Guanine-Containing Antiviral Drugs [J].
Cheng, Yaofeng ;
Vapurcuyan, Arpine ;
Shahidullah, Mohammad ;
Aleksunes, Lauren M. ;
Pelis, Ryan M. .
DRUG METABOLISM AND DISPOSITION, 2012, 40 (03) :617-624
[6]  
Cotte L, 2014, 21 C RETR OPP INF BO
[7]  
Crespo M, 2007, ANTIVIR THER, V12, P1217
[8]   Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin [J].
Dahari, Harel ;
Markatou, Marianthi ;
Zeremski, Marija ;
Haller, Ivan ;
Ribeiro, Ruy M. ;
Licholai, Teresa ;
Perelson, Alan S. ;
Talal, Andrew H. .
JOURNAL OF HEPATOLOGY, 2007, 47 (01) :23-30
[9]   Ribavirin concentration in the later stages of 48 week pegylated interferon-α2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response [J].
Furusyo, Norihiro ;
Murata, Masayuki ;
Ogawa, Eiichi ;
Toyoda, Kazuhiro ;
Ihara, Takeshi ;
Ikezaki, Hiroaki ;
Hayashi, Takeo ;
Koga, Tsunehisa ;
Kainuma, Mosaburo ;
Hayashi, Jun .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (05) :1127-1139
[10]  
Glue P, 1999, SEMIN LIVER DIS, V19, P17